Noteworthy, along with Sp1, the reactivation of the oncosuppressive miR-29b was accompanied by the down-regulation of other miR-29b canonical targets, i.e., MCL-1 and CDK6, suggesting a pleiotropic anti-tumor activity of this drug in MM cells. Here, CDK6 is linked to Miyoshi myopathy.